AbCellera Biologics Inc.
ABCL
$10.97
$0.625.94%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 101.28% | 242.66% | 160.55% | 7.16% | -0.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 101.28% | 242.66% | 160.55% | 7.16% | -0.54% |
| Cost of Revenue | 17.19% | 12.04% | 11.70% | 7.66% | 1.20% |
| Gross Profit | 3.15% | 24.14% | 19.30% | -7.78% | -1.63% |
| SG&A Expenses | -17.14% | -8.76% | -2.64% | -0.26% | 1.91% |
| Depreciation & Amortization | -10.91% | -60.10% | -62.33% | -103.95% | -48.23% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.22% | -7.17% | -6.22% | -22.41% | -7.54% |
| Operating Income | 8.72% | 27.04% | 23.22% | 25.57% | 8.40% |
| Income Before Tax | 1.02% | 17.32% | 11.38% | -1.36% | -11.17% |
| Income Tax Expenses | 3.05% | 29.40% | 16.93% | -26.08% | -29.84% |
| Earnings from Continuing Operations | 0.61% | 14.24% | 10.10% | 2.34% | -8.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 0.61% | 14.24% | 10.10% | 2.34% | -8.07% |
| EBIT | 8.72% | 27.04% | 23.22% | 25.57% | 8.40% |
| EBITDA | -8.54% | 4.45% | -2.72% | 10.68% | 14.17% |
| EPS Basic | 2.49% | 15.53% | 11.37% | 3.92% | -6.32% |
| Normalized Basic EPS | 2.50% | 18.22% | 12.29% | 18.00% | -4.98% |
| EPS Diluted | 3.02% | 15.45% | 11.52% | 5.38% | -4.17% |
| Normalized Diluted EPS | 2.50% | 18.22% | 12.29% | 18.00% | -4.98% |
| Average Basic Shares Outstanding | 1.74% | 1.51% | 1.49% | 1.57% | 1.69% |
| Average Diluted Shares Outstanding | 1.74% | 1.51% | 1.49% | 1.57% | 1.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |